Little Green Pharma (ASX:LGP) Revenue: A$42.43 Mil (TTM As of Mar. 2026)


What is Little Green Pharma Revenue?

Little Green Pharma ASX:LGP Revenue is A$42.43 Mil as of Mar. 2026. The stock has 3 warning signs investors should review.

Little Green Pharma's revenue for the six months ended in Mar. 2026 was A$23.24 Mil. Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was A$42.43 Mil. Little Green Pharma's Revenue per Share for the six months ended in Mar. 2026 was A$0.08. Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.14.

Warning Sign:

Little Green Pharma Ltd revenue growth has slowed down over the past 12 months.

During the past 12 months, the average Revenue per Share Growth Rate of Little Green Pharma was 13.90% per year. During the past 3 years, the average Revenue per Share Growth Rate was 21.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was 48.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 7 years, Little Green Pharma's highest 3-Year average Revenue per Share Growth Rate was 71.70% per year. The lowest was 21.20% per year. And the median was 42.70% per year.

Little Green Pharma  (ASX:LGP) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Little Green Pharma Revenue Related Terms

Little Green Pharma Revenue Historical Data

* Premium members only.

The historical data trend for Little Green Pharma's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Little Green Pharma Revenue Chart

Little Green Pharma Annual Data
Trend Jun19 Jun20 Jun21 Mar23 Mar24 Mar25 Mar26
Revenue
Get a 7-Day Free Trial 7.00 19.57 25.63 36.82 42.43

Little Green Pharma Semi-Annual Data
Jun19 Jun20 Dec20 Jun21 Dec21 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.98 17.51 19.31 19.18 23.24

ASX:LGP vs ZTS, UTHR: Revenue Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Little Green Pharma's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Little Green Pharma Revenue vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Little Green Pharma's Revenue distribution charts can be found below:

* The bar in red indicates where Little Green Pharma's Revenue falls into.


Little Green Pharma Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$42.43 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of A$42.43 Mil mean?
Little Green Pharma (ASX:LGP) has a Revenue of A$42.43 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Little Green Pharma and its competitors.
Is Little Green Pharma's Revenue too high?
Little Green Pharma's current Revenue is A$42.43 Mil.
How does Little Green Pharma's Revenue compare to ZTS and UTHR?
Little Green Pharma's Revenue of A$42.43 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Drug Manufacturers company?
A good Revenue depends on the Drug Manufacturers industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Little Green Pharma and its competitors. Little Green Pharma's current Revenue is A$42.43 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Little Green Pharma stock overvalued right now?
Based on GuruFocus' analysis, Little Green Pharma (ASX:LGP) is currently considered Significantly Undervalued. The stock's GF Value™ is A$0.17, compared to a current price of A$0.07 — trading 58.8% below its estimated fair value. The current Revenue is A$42.43 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Little Green Pharma (ASX:LGP), the current Revenue is A$42.43 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Little Green Pharma Business Description

Address 13A Bedbrook Place, Shenton Park, West Perth, Perth, WA, AUS, 6008
Little Green Pharma Ltd is engaged in the vertically integrated medicinal cannabis business. The business activities of the company include cultivation, production, research and development, manufacturing, and distribution of medicinal cannabis products. The company's two key types of products available at Little Green Pharma are oils (which are ingested) and flowers (which are usually inhaled through vaporizing). It offers LGP-branded medicinal cannabis oil products in the Australian and European markets. The Group is organized into two operating segments: Australia and Europe (cultivation, production and distribution of cannabis products to Australian and European customers).